Latest Regulatory Approvals News

Locksley Resources has gained critical regulatory approval and secured contractors to advance its Mojave Project, accelerating exploration of antimony and rare earth elements in California.

EV Resources is rapidly progressing its Los Lirios Antimony Project in Mexico, defining drill-ready targets ahead of a maiden drilling campaign amid growing global demand for critical minerals.

Altamin Limited has extended the closing date for its retail entitlement offer to 15 October 2025, aiming to raise up to AUD 6.46 million to support its mining projects.

Amplitude Energy Limited has announced a proposed 11-for-1 share consolidation, pending shareholder approval at its upcoming AGM. This move aims to streamline its capital structure following a recent entitlement offer.

New Hope Corporation has updated its final dividend details for FY2025, confirming a fully franked payout of 15 cents per share and revising the dividend reinvestment plan price to $4.01.

XTC Lithium Limited will be delisted from the ASX after over two years of suspension, choosing instead to focus on advancing its Carachi Pampa Lithium Brine Project through partnerships and operational progress.

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.

NexGen Energy has launched a dual equity offering, raising approximately C$400 million in North America and AUD 400 million in Australia to advance its flagship Rook I uranium project and support corporate growth.

Octava Minerals reports impressive bioleaching recoveries of critical minerals from its Byro project, prompting plans to acquire full ownership and expand exploration activities.

Memphasys Limited has announced a pro-rata entitlement offer to raise approximately $1.12 million, issuing new shares at $0.003 each with free attaching options, aiming to fund the commercialisation of its Felix™ system and strengthen working capital.

(E,E)-bisantrene, Race Oncology’s lead anticancer candidate, operates by binding to G4-DNA and RNA structures, revealing a novel mechanism that disrupts key cancer drivers including the MYC gene.

Audalia Resources has completed a $500,000 placement to a sophisticated investor, issuing 20 million shares to fund critical development stages at its Medcalf Project. The capital injection aims to advance mining design, permits, and approvals while bolstering working capital.